
United States
If you know about waste, fraud, abuse, misconduct, or whistleblower reprisal relating to a Department of Justice (DOJ) employee, program, contract, or grant you may report it to the DOJ OIG Hotline. The DOJ OIG has jurisdiction over disclosures involving DOJ employees, programs, contracts, and grants, including disclosures concerning these DOJ components:
- Federal Bureau of Investigation
- Drug Enforcement Administration
- Federal Bureau of Prisons
- U.S. Marshals Service
- Bureau of Alcohol, Tobacco, Firearms, and Explosives
- United States Attorneys Offices
- employees who work in other Divisions or Offices in the Department of Justice
The DOJ OIG also has jurisdiction to investigate allegations of whistleblower retaliation involving:
- Employees of the Federal Bureau of Investigation
- Employees of DOJ contractors, subcontractors, grantees, and subgrantees
- DOJ employees who believe their security clearance or access to classified information has been taken in retaliation for whistleblowing
The following matters are NOT generally investigated by the DOJ OIG.
- 911 emergencies
- EEO Complaints (For such matters, please refer to the DOJ Equal Employment Opportunity Office.)
- Misconduct by judges at the federal, state, or local level. (For more information on judicial misconduct by federal judges, please refer to the U.S. Courts.)
- State and local police departments (unless the misconduct concerns DOJ grant funds)
- State and Local prisons (unless the complaint involves a U.S. Marshals Service inmate)
Nicholas County Man Pleads Guilty to Federal Fraud Charge
Former Bureau of Prisons Correctional Officer Sentenced to Federal Prison for Bribery
Recidivist Fraudster And Co-Conspirator Charged In Covid-19 Relief Loan, Identity Theft, And Money Laundering Scheme
Federal Correctional Officer Charged With Sexual Abuse Of An Inmate
Investigative Summary: Findings of Misconduct by a then Senior Official with the Drug Enforcement Administration for Misuse of Official Position Related to Giving Preferential Treatment to a Pharmaceutical Company, and Related Misconduct
Semiannual Report to Congress April 1, 2021 –September 30, 2021
Recommendations Issued by the Office of the Inspector General That Were Not Closed as of September 30, 2021
This report contains information about recommendations from the OIG's audits, evaluations, reviews, and other reports that the OIG had not closed as of the specified date because it had not determined that the Department of Justice (DOJ) or a non-DOJ federal agency had fully implemented them. The...